JP7541606B2 - Ｆｇｆｒ３阻害剤の共結晶形態 - Google Patents

Ｆｇｆｒ３阻害剤の共結晶形態 Download PDF

Info

Publication number
JP7541606B2
JP7541606B2 JP2023145013A JP2023145013A JP7541606B2 JP 7541606 B2 JP7541606 B2 JP 7541606B2 JP 2023145013 A JP2023145013 A JP 2023145013A JP 2023145013 A JP2023145013 A JP 2023145013A JP 7541606 B2 JP7541606 B2 JP 7541606B2
Authority
JP
Japan
Prior art keywords
cancer
urothelial
fgfr3
bladder cancer
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023145013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024037713A (ja
JP2024037713A5 (enExample
Inventor
アンドリュー コーツ，デイビッド
ラケル ヒルデン，ロリ
クミネック，ジスレーヌ
ピーターソン，ジェフリー・エイ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024037713A publication Critical patent/JP2024037713A/ja
Publication of JP2024037713A5 publication Critical patent/JP2024037713A5/ja
Priority to JP2024136962A priority Critical patent/JP2024153948A/ja
Application granted granted Critical
Publication of JP7541606B2 publication Critical patent/JP7541606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023145013A 2022-09-07 2023-09-07 Ｆｇｆｒ３阻害剤の共結晶形態 Active JP7541606B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024136962A JP2024153948A (ja) 2022-09-07 2024-08-16 Ｆｇｆｒ３阻害剤の共結晶形態

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024136962A Division JP2024153948A (ja) 2022-09-07 2024-08-16 Ｆｇｆｒ３阻害剤の共結晶形態

Publications (3)

Publication Number Publication Date
JP2024037713A JP2024037713A (ja) 2024-03-19
JP2024037713A5 JP2024037713A5 (enExample) 2024-05-02
JP7541606B2 true JP7541606B2 (ja) 2024-08-28

Family

ID=88204177

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023145013A Active JP7541606B2 (ja) 2022-09-07 2023-09-07 Ｆｇｆｒ３阻害剤の共結晶形態
JP2024136962A Pending JP2024153948A (ja) 2022-09-07 2024-08-16 Ｆｇｆｒ３阻害剤の共結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024136962A Pending JP2024153948A (ja) 2022-09-07 2024-08-16 Ｆｇｆｒ３阻害剤の共結晶形態

Country Status (16)

Country Link
US (1) US20240116932A1 (enExample)
EP (1) EP4584270A1 (enExample)
JP (2) JP7541606B2 (enExample)
KR (1) KR20250057022A (enExample)
CN (1) CN120187720A (enExample)
AR (1) AR130417A1 (enExample)
AU (1) AU2023338199A1 (enExample)
CA (1) CA3266872A1 (enExample)
CL (1) CL2025000596A1 (enExample)
CO (1) CO2025002467A2 (enExample)
CR (1) CR20250077A (enExample)
DO (1) DOP2025000054A (enExample)
IL (1) IL319342A (enExample)
PE (1) PE20251400A1 (enExample)
TW (1) TWI862146B (enExample)
WO (1) WO2024054814A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258859A1 (en) 2005-12-08 2009-10-15 Ssci, Inc. Metronidazole cocrystals and imipramine cocrystals
JP2013014584A (ja) 2011-06-09 2013-01-24 Lab Servier アゴメラチンの新規な共結晶、その調製のための方法及びそれを含む医薬組成物
CN102964384A (zh) 2012-11-09 2013-03-13 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
CN111574359A (zh) 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
JP2021523876A (ja) 2018-02-13 2021-09-09 トランスジェネックス ナノバイオテック、インコーポレイテッド 癌治療のためのタミバロテンの新規の結晶形態
CN113943284A (zh) 2020-07-15 2022-01-18 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180207B2 (en) * 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
TW202402754A (zh) 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258859A1 (en) 2005-12-08 2009-10-15 Ssci, Inc. Metronidazole cocrystals and imipramine cocrystals
JP2013014584A (ja) 2011-06-09 2013-01-24 Lab Servier アゴメラチンの新規な共結晶、その調製のための方法及びそれを含む医薬組成物
CN102964384A (zh) 2012-11-09 2013-03-13 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
JP2021523876A (ja) 2018-02-13 2021-09-09 トランスジェネックス ナノバイオテック、インコーポレイテッド 癌治療のためのタミバロテンの新規の結晶形態
CN111574359A (zh) 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284A (zh) 2020-07-15 2022-01-18 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途

Also Published As

Publication number Publication date
DOP2025000054A (es) 2025-03-31
CR20250077A (es) 2025-04-02
TW202428260A (zh) 2024-07-16
TWI862146B (zh) 2024-11-11
CN120187720A (zh) 2025-06-20
CL2025000596A1 (es) 2025-04-25
CO2025002467A2 (es) 2025-03-17
PE20251400A1 (es) 2025-05-22
JP2024037713A (ja) 2024-03-19
JP2024153948A (ja) 2024-10-29
WO2024054814A1 (en) 2024-03-14
AR130417A1 (es) 2024-12-04
KR20250057022A (ko) 2025-04-28
US20240116932A1 (en) 2024-04-11
IL319342A (en) 2025-05-01
AU2023338199A1 (en) 2025-03-20
EP4584270A1 (en) 2025-07-16
CA3266872A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
EP3473626B1 (en) Pyrrolopyrimidine crystal for preparing jak inhibitor
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
JP7541606B2 (ja) Ｆｇｆｒ３阻害剤の共結晶形態
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
AU2020242723B2 (en) BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CN110256405A (zh) 5-烃基-n-取代芳基吡啶酮衍生物及其制备方法和用途
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
AU2014280710B2 (en) New polymorphic forms of Icotinib phosphate and uses thereof
CN111892536B (zh) 取代的喹啉甲酰胺类化合物及其用途
CN111362871B (zh) 取代的吡啶-2-甲酰胺类化合物及其用途
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
HK40080650A (en) Salt and crystalline forms of fgfr4 inhibitors and uses thereof
JP2023510932A (ja) アザインドール誘導体の結晶形及びその応用
WO2019218928A1 (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
TW201512203A (zh) 埃克替尼馬來酸鹽的晶型及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240423

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240816

R150 Certificate of patent or registration of utility model

Ref document number: 7541606

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150